Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer



Status:Active, not recruiting
Conditions:Lung Cancer, Lung Cancer, Colorectal Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:June 6, 2017
End Date:December 31, 2020

Use our guide to learn which trials are right for you!

A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to
see how well they work with or without high or low-dose radiation therapy in treating
patients with colorectal or non-small cell lung cancer that has spread to other parts of the
body. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the
ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill
tumor cells and shrink tumors. Giving durvalumab and tremelimumab with radiation therapy may
work better in treating patients with colorectal or non-small cell lung cancer.

PRIMARY OBJECTIVES:

I. To assess safety and tolerability of combined checkpoint blockade with MEDI4736
(durvalumab) and tremelimumab alone or with high or low-dose radiation in non-small cell lung
cancer (NSCLC). (NSCLC Cohort) II. To compare the overall response (excluding the irradiated
lesion[s]) between combined checkpoint blockade with MEDI4736 and tremelimumab alone or
combined checkpoint blockade with low or high dose radiation. (NSCLC Cohort) III. To assess
safety and tolerability of combined checkpoint blockade with MEDI4736 and tremelimumab with
high or low-dose radiation. (Colorectal Cohort) IV. To determine the overall response rate
(excluding the irradiated lesion[s]) with combined checkpoint blockade with MEDI4736 and
tremelimumab with either low or high dose radiation. (Colorectal Cohort)

SECONDARY OBJECTIVES:

I. To estimate median progression-free survival and overall survival. (NSCLC Cohort) II. To
determine local control within the irradiated field(s) and abscopal response rates. (NSCLC
Cohort) III. To evaluate associations between PD-L1 expression as well as levels of
infiltrating CD3+, CD8+ T-cells and overall response. (NSCLC Cohort) IV. To explore changes
in PD-L1 expression, circulating T-cell populations, T-cell infiltration, ribonucleic acid
(RNA) expression, spatial relationship of immune markers, and mutational burden as a result
of low or high dose radiation. (NSCLC Cohort) V. To estimate median progression-free survival
and overall survival. (Colorectal Cohort) VI. To determine local control within the
irradiated field and abscopal response rates. (Colorectal Cohort) VII. To evaluate
associations between PD-L1 expression as well as levels of infiltrating CD3+ CD8+ T-cells and
overall response. (Colorectal Cohort) VIII. To evaluate changes between PD-L1 expression as
well as levels of infiltrating CD3+, CD8+ T-cells induced by targeted low or high dose
radiation. (Colorectal Cohort) IX. To explore changes in circulating T-cell populations,
T-cell infiltration, RNA expression, spatial relationship of immune markers, and mutational
burden as a result of low or high dose radiation. (Colorectal Cohort)

OUTLINE: Patients with NSCLC are randomized to Arm A, B, or C. Patients with colorectal
cancer are randomized to Arm B or C.

COHORT 1: Patients with NSCLC are randomized to 1 of 3 arms.

ARM A: Patients receive tremelimumab intravenously (IV) and durvalumab IV over 60 minutes
every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable
toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination
dose for up to 9 additional doses.

ARM B: Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2,
patients receive high dose radiation therapy once per day (QD) over 10 days for up to 3
fractions.

ARM C: Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2,
patients receive low dose radiation therapy every 6 hours twice per day (BID) on weeks 2, 6,
10 and 14.

After completion of study treatment, patients are followed for up to 12 weeks.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed non-small cell lung
cancer (cohort 1) or colorectal cancer (cohort 2)

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded for
non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with
conventional techniques or as >= 10 mm (>= 1.5 cm) with spiral computed tomography
(CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam

- Patients in both cohorts must have progressive disease following prior therapy;
specifically:

- Cohort 1 (NSCLC): Patients must have evidence of radiologic or clinical disease
progression during previous treatment with systemic PD-1 directed therapy and/or
have been deemed not to derive clinical benefit from PD-1 directed treatment;
this includes patients who demonstrated an initial response and subsequent
progression; no prior treatment with chemotherapy or targeted agents are
required; intervening therapy is allowed between previous PD-1 directed treatment
and there is no required interval from prior PD-1 treatment required; PD-1
directed treatment includes treatment with antibodies targeting the PD-1 receptor
such as pembrolizumab or nivolumab, as well as PD-L1 targeted antibodies such as
MEDI4736 (durvalumab), atezolizumab and avelumab; these agents may have been
administered as part of a clinical trial

- Cohort 2 (colorectal cancer): Patients must have progressed on >= one line
chemotherapy

- At least 21 days must have elapsed from prior systemic therapy (chemotherapy or
radiation)

- Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 60%)
and life expectancy greater than 6 months; furthermore, enrollment of patients with
greater than 10 measurable lesions is discouraged

- Patients must have normal organ and marrow function independent of transfusion for at
least 7 days prior to screening and independent of growth factor support for at least
14 days prior to screening

- Hemoglobin (Hgb) >= 9 g/dl

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Total bilirubin =< 1.5 x normal institutional limits; this will not apply to patients
with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia
[predominantly unconjugated bilirubin] in the absence of evidence of hemolysis or
hepatic pathology), who will be allowed in consultation with their physician

- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
= < 2.5 x institutional upper limit of normal; for patients with hepatic metastases,
ALT and AST =< 5 x ULT

- Measured creatinine clearance (CL) > 40 mL/min OR calculated creatinine clearance (CL)
> 40 mL/min as determined by Cockcroft-Gault (using actual body weight)

- Patients must have at least one lesion that has not previously been irradiated (and is
not within a previously radiated field) and for which palliative radiation is
potentially indicated and could be safely delivered at the radiation doses specified
in this protocol; this lesion must not be the only measurable lesion so that it is
still possible to determine the response rate outside of the radiation treatment
field; this lesion must not be within the central nervous system (CNS) (brain or
spinal cord) or requiring urgent or emergent palliative radiation given the timing of
radiation specified on this protocol; furthermore, this lesion:

- For cohort 1 (NSCLC cohort) - the lesion to be irradiated must be in the lung,
lymph nodes, adrenal gland or liver

- For cohort 2 (colorectal cohort) - the lesion to be irradiated must be in the
liver

- Evidence of post-menopausal status or negative urinary or serum pregnancy test for
female pre-menopausal patients is required; women will be considered post-menopausal
if they have been amenorrheic for 12 months without an alternative medical cause; the
following age-specific requirements apply:

- Women < 50 years of age would be considered post-menopausal if they have been
amenorrheic for 12 months or more following cessation of exogenous hormonal
treatments and if they have luteinizing hormone and follicle stimulating hormone
levels in the post-menopausal range for the institution or underwent surgical
sterilization (bilateral oophorectomy or hysterectomy)

- Women >= 50 years of age would be considered post-menopausal if they have been
amenorrheic for 12 months or more following cessation of all exogenous hormonal
treatments, had radiation-induced oophorectomy with last menses > 1 year ago, had
chemotherapy-induced menopause with > 1 year interval since last menses, or
underwent surgical sterilization (bilateral oophorectomy or hysterectomy)

- Females of childbearing potential who are sexually active with a non sterilized male
partner must use at least 1 highly effective method of contraception from the time of
screening and must agree to continue using such precautions for 180 days after the
last dose of durvalumab + tremelimumab combination therapy or 90 days after the last
dose of durvalumab monotherapy; non-sterilized male partners of a female patient must
use male condom plus spermicide throughout this period; cessation of birth control
after this point should be discussed with a responsible physician; not engaging in
sexual activity for the total duration of the drug treatment and the drug washout
period is an acceptable practice; however, periodic abstinence, the rhythm method, and
the withdrawal method are not acceptable methods of birth control; female patients
should also refrain from breastfeeding throughout this period

- Non-sterilized males who are sexually active with a female partner of childbearing
potential must use a male condom plus spermicide from screening through 180 days after
receipt of the final dose of durvalumab + tremelimumab combination therapy or 90 days
after receipt of the final dose of durvalumab monotherapy; not engaging in sexual
activity is an acceptable practice; however, occasional abstinence, the rhythm method,
and the withdrawal method are not acceptable methods of contraception; male patients
should refrain from sperm donation throughout this period

- Female partners (of childbearing potential) of male patients must also use a highly
effective method of contraception throughout this period

- Should a woman become pregnant or suspect she is pregnant while she or her partner is
participating in this study, she should inform her treating physician immediately

- Ability of a patient or a Legally Authorized Representative (LAR) to understand and
the willingness to sign a written informed consent document

- Body weight > 30 kg

- Must have a life expectancy of at least 12 weeks

- Cohort 1 (NSCLC cohort)

- Ability to undergo a fresh tumor biopsy for the purpose of screening for this
clinical trial (including able and willing to give valid written consent) to
ability or to provide an available archival tumor sample taken less than 3 months
prior to study enrollment (and not obtained prior to progression on a PD-1/PD-L1
inhibitor) if a fresh tumor biopsy is not feasible with an acceptable clinical
risk; tumor lesions used for fresh biopsies should be the same lesions to be
irradiated when possible and should not be the same lesions used as Response
Evaluation Criteria in Solid Tumors (RECIST) target lesions, unless there are no
other lesions accessible; additional, optional archival tumor tissue is also
requested from before the prior PD-1 directed therapy

- Cohort 2 (colorectal cohort)

- Ability to undergo a fresh tumor biopsy for the purpose of screening for this
clinical trial (including able and willing to give valid written consent) to
ability or to provide an available archival tumor sample taken less than 3 months
prior to study enrollment if a fresh tumor biopsy is not feasible with an
acceptable clinical risk; tumor lesions used for fresh biopsies should be the
same lesions to be irradiated when possible and should not be the same lesions
used as RECIST target lesions, unless there are no other lesions accessible

- Microsatellite stable (MSS) tumor as documented by either:

- Immunohistochemistry (IHC) testing that does not suggest loss of MLH-1,
MSH-2, PMS2 or MSH6

- Polymerase chain reaction (PCR) testing that does not suggest microsatellite
instability (MSI)

Exclusion Criteria:

- Patients who have had systemic (chemotherapy, biologic therapy or radiotherapy) within
3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study

- Receipt of prior radiotherapy or condition for any reason that would contribute
radiation dose that would exceed tolerance of normal tissues, at the discretion of the
treating physician

- Patients who have not recovered from adverse events due to prior anti-cancer therapy
(i.e., have residual toxicities > grade 1)

- Patients who are receiving any other investigational agents

- Patients with untreated brain metastases, spinal cord compression, or leptomeningeal
carcinomatosis should be excluded from this clinical trial; patients whose brain
metastases have been treated may participate provided they show radiographic stability
(defined as 2 brain images, both of which are obtained after treatment to the brain
metastases; these imaging scans should both be obtained at least four weeks apart and
show no evidence of intracranial progression); in addition, any neurologic symptoms
that developed either as a result of the brain metastases or their treatment must have
resolved or be stable either, without the use of steroids, or are stable on a steroid
dose of =< 10 mg/day of prednisone or its equivalent (and anti-convulsants) for at
least 14 days prior to the start of treatment

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to tremelimumab and MEDI4736 or previous toxicity attributed to MEDI4736
or other PD-1 or PD-L1 directed therapy that led to drug discontinuation

- Prior exposure to immune-mediated therapy, including durvalumab and tremelimumab,
except for anti-PD-1 or anti-PD-L1 therapy (including durvalumab) in NSCLC patients;
this includes anti-CTLA-4 agents (prior treatment with these agents is NOT allowed in
either cohort) and, excludes therapeutic anticancer vaccines, excluding therapeutic
anticancer vaccines; exposure to other investigational agents may be permitted after
discussion with the study principal investigator (PI)

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with MEDI4736 (durvalumab), tremelimumab and radiation

- Female patients who are pregnant or breastfeeding or male or female patients of
reproductive potential who are not willing to employ effective birth control from
screening to 90 days after the last dose of durvalumab monotherapy or 180 days after
the last dose of durvalumab + tremelimumab combination therapy, whichever is later

- Human immunodeficiency virus (HIV)-positive patients are ineligible; appropriate
studies will be undertaken in patients receiving combination antiretroviral therapy
when indicated

- Any concurrent chemotherapy, immune therapy, biologic, hormonal therapy for cancer
treatment

- Current or prior use of immunosuppressive medication within 14 days before the first
dose of their assigned IP; the following are exceptions to this criterion:

- Intranasal, inhaled, topical steroids, or local steroid injections (e.g.,
intra-articular injection)

- Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of
prednisone or its equivalent

- Steroids as pre-medication for hypersensitivity reactions (e.g., CT scan
pre-medication)

- Major surgical procedure (as defined by the investigator) within 28 days prior to the
first dose of IP; Note: local surgery of isolated lesions for palliative intent is
acceptable

- History of allogeneic organ transplantation

- Active or prior documented autoimmune or inflammatory disorders (including
inflammatory bowel disease, diverticulitis [with the exception of diverticulosis];
sarcoidosis syndrome, or other serious gastrointestinal [GI] chronic conditions
associated with diarrhea; systemic lupus erythematosus; Wegener syndrome
[granulomatosis with polyangiitis]; myasthenia gravis; Graves disease; rheumatoid
arthritis; hypophysitis; uveitis, sarcoidosis syndrome, etc.) within the past 3 years
prior to the start of treatment; the following are exceptions to this criterion:

- Patients with vitiligo or alopecia

- Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
hormone replacement or psoriasis not requiring systemic treatment

- Any chronic skin condition that does not require systemic therapy

- Patients without active disease in the last 5 years may be included but only
after consultation with the study physician

- Patients with celiac disease controlled by diet alone

- History of another primary malignancy except for

- Malignancy treated with curative intent and with no known active disease >= 5
years before the first dose of study drug and of low potential risk for
recurrence

- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
of disease

- Adequately treated carcinoma in situ without evidence of disease (e.g., cervical
cancer in situ)

- Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from
electrocardiograms (ECGs) using Fridericia's correction; abnormal ECGs should be
repeated

- History of active primary immunodeficiency

- Known history of previous clinical diagnosis of tuberculosis

- Active infection including hepatitis B (known positive hepatitis B virus [HBV] surface
antigen [HBsAg]) result or, hepatitis C; patients with a past or resolved HBV
infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence
of HBsAg) are eligible; patients positive for hepatitis C (HCV) antibody are eligible
only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA); negative
serologies documented over the past year are sufficient evidence of this

- Receipt of live, attenuated vaccine within 30 days prior to the first dose of
investigational treatment; Note: patients, if enrolled, should not receive live
vaccine during the study and up to 30 days after the last dose of investigational
treatment

- Any condition that, in the opinion of the investigator, would interfere with evaluati
We found this trial at
42
sites
Pittsburgh, Pennsylvania 15232
Principal Investigator: Liza C. Villaruz
Phone: 412-647-8073
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Jonathan D. Schoenfeld
Phone: 888-823-5923
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Jonathan D. Schoenfeld
Phone: 617-667-9925
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Ryan D. Gentzler
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Sarah W. Gordon
Phone: 888-823-5923
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Olatunji B. Alese
Phone: 888-946-7447
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Olatunji B. Alese
Phone: 404-778-1868
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Olatunji B. Alese
Phone: 888-823-5923
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
410-328-7904
Principal Investigator: Christian D. Rolfo
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Jonathan D. Schoenfeld
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
?
mi
from
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Jonathan D. Schoenfeld
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Carrie Lee
Phone: 877-668-0683
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Kevin L. Stephans
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Erin M. Bertino
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
10 Barnes West Drive
Creve Coeur, Missouri 63141
Principal Investigator: Haeseong Park
Phone: 800-600-3606
?
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
(313) 833-1785
Principal Investigator: Hirva Mamdani
Phone: 313-576-9790
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: James L. Abbruzzese
Phone: 888-275-3853
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Farmington Hills, Michigan 48334
Principal Investigator: Hirva Mamdani
Phone: 313-576-9790
?
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
111 Goose Lane
Guilford, Connecticut 06437
Principal Investigator: Stacey M. Stein
Phone: 203-785-5702
?
mi
from
Guilford, CT
Click here to add this to my saved trials
Hartford, Connecticut 06105
Principal Investigator: Stacey M. Stein
Phone: 203-785-5702
?
mi
from
Hartford, CT
Click here to add this to my saved trials
4500 San Pablo Rd S
Jacksonville, Florida 32224
(904) 953-2000
Principal Investigator: Joleen M. Hubbard
Phone: 855-776-0015
Mayo Clinic Florida Thousands of people come to Mayo Clinic in Jacksonville, Fla., annually for...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Lexington, Kentucky
Principal Investigator: Ronald C. McGarry
Phone: 859-257-3379
?
mi
from
Lexington, KY
Click here to add this to my saved trials
1983 Marengo St
Los Angeles, California 90033
(323) 226-2622
Principal Investigator: Heinz-Josef Lenz
Phone: 323-865-0451
Los Angeles County-USC Medical Center The origins of LAC+USC Medical Center date back to 1878,...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: Heinz-Josef Lenz
Phone: 323-865-0451
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
600 Highland Ave
Madison, Wisconsin 53792
(608) 263-6400
Principal Investigator: Nataliya V. Uboha
Phone: 800-622-8922
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
?
mi
from
Madison, WI
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Dana B. Cardin
Phone: 800-811-8480
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Principal Investigator: Salma K. Jabbour
Phone: 732-235-8675
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Principal Investigator: Salma K. Jabbour
Phone: 732-235-8675
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
New Haven, Connecticut 06510
Principal Investigator: Stacey M. Stein
Phone: 203-785-5702
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Stacey M. Stein
Phone: 203-785-5702
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
North Haven, Connecticut 06473
Principal Investigator: Stacey M. Stein
Phone: 203-785-5702
?
mi
from
North Haven, CT
Click here to add this to my saved trials
111 S 11th St
Philadelphia, Pennsylvania 19107
(215) 955-6000
Principal Investigator: Jennifer M. Johnson
Phone: 215-955-6084
Thomas Jefferson University Hospital Our hospitals in Center City Philadelphia share a 13-acre campus with...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona
Principal Investigator: Joleen M. Hubbard
Phone: 855-776-0015
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Joleen M. Hubbard
Phone: 855-776-0015
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Arta M. Monjazeb
Phone: 916-734-3089
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63129
Principal Investigator: Haeseong Park
Phone: 800-600-3606
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Haeseong Park
Phone: 800-600-3606
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
150 Entranceway Drive
Saint Peters, Missouri 63376
Principal Investigator: Haeseong Park
Phone: 800-600-3606
?
mi
from
Saint Peters, MO
Click here to add this to my saved trials
13400 E. Shea Blvd.
Scottsdale, Arizona 85259
480-301-8000
Principal Investigator: Joleen M. Hubbard
Phone: 855-776-0015
Mayo Clinic Arizona Mayo Clinic in Arizona provides medical care for thousands of people from...
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Toronto, Ontario
Principal Investigator: Rebecca K. Wong
Phone: 416-946-4501
?
mi
from
Toronto,
Click here to add this to my saved trials
Trumbull, Connecticut 06611
Principal Investigator: Stacey M. Stein
Phone: 203-785-5702
?
mi
from
Trumbull, CT
Click here to add this to my saved trials
Waterford, Connecticut 06385
Principal Investigator: Stacey M. Stein
Phone: 203-785-5702
?
mi
from
Waterford, CT
Click here to add this to my saved trials